Ardelyx Shares Drop Following Loss in Appeal Against Medicare Coverage Decision
Ardelyx (ARDX) shares fell approximately 6% after the company lost an appeal against a decision by the Health and Human Services Department to remove Part D coverage for its kidney disease therapy, Xphozah. The ruling could impact patient access and revenue from this treatment.
Tickers: $ARDX
Topics: healthcare policy lawsuit outcome stock price movement